tbuckley/cabot-search huggingface dataset:
Abstract 21031: Paroxysmal Supraventricular Tachycardia is Associated With Atrial Enhancement Detected With Late Gadolinium Enhanced MRI
Authors: Mobin Kheirkhahan, Alex Baher, Johannes Siebermair, Gagandeep Kaur, Benjamin A Steinberg, Frederick T Han, Mihail G Chelu, Nassir F Marrouche
Journal: Circulation (2017)

Introduction: Paroxysmal supraventricular tachycardias (PSVT) are among common cardiac arrhythmias. Atrial fibrosis correlates with several cardiac dysrhythmias and while its role is well described in atrial fibrillation, its role in PSVTs is less clear. We sought to investigate the extent of left atrial (LA) and right atrial (RA) enhancement in patients with supraventricular tachycardia (SVT) without a history of atrial fibrillation. Methods and Results: In our case-control study the information of 212 patients was collected. 30 patients with PSVT (age 48.6 ± 20.1 and 43% male) and 182 patients with no known arrhythmic disorder as the control group (age 50.3 ± 14.7 and 66% males) matched for age, LA volume, left ventricular ejection fraction (LVEF) and other comorbidities such as hypertension, hyperlipidemia, diabetes, coronary artery disease, heart failure, and smoking. LA and RA fibrosis were quantified by the Late Gadolinium Enhanced Magnetic Resonance Imaging (LGE-MRI) using signal intensity analysis. The average % LA wall enhancements were 15.2% ± 6.3% in the SVT group and 10.7% ± 6.5% in the control group (p = 0.001) while for RA enhancement they were 11.1% ± 5% and 8.1% ± 4.1% for the SVT and control groups respectively (p = 0.009). Our logistic regression analysis showed that for each 1% increase in LA and RA enhancement, there was a 19% and 16% greater chance of having PSVT (p = 0.006, p = 0.013 respectively). Conclusions: Our study suggests that the extent of atrial fibrosis (either in the left or right atrium), quantified using LGE-MRI, is higher among patients with PSVT. The impact of increased atrial fibrosis in this patient population, could be correlated with other major adverse cardiac events.
Higher Coronary Plaque Burden in Psoriatic Arthritis Is Independent of Metabolic Syndrome and Associated With Underlying Disease Severity
Authors: Agnes Szentpetery, Gerard M. Healy, Darragh Brady, Muhammad Haroon, Phil Gallagher, Ciaran E. Redmond, Hannah Fleming, John Duignan, Jonathan D. Dodd, Oliver FitzGerald
Journal: Arthritis & Rheumatology (2017)

Objective To examine the effect of metabolic syndrome and psoriatic disease–related variables on coronary plaque burden in psoriatic arthritis (PsA) patients. Methods Fifty PsA patients without symptoms of coronary artery disease ( CAD ) (25 with metabolic syndrome and 25 without metabolic syndrome) and 50 age‐ and sex‐matched controls underwent 64‐slice coronary computed tomography angiography. Plaque localization, segment involvement score ( SIS ), segment stenosis score ( SSS ), and total plaque volume ( TPV ) were calculated. Plaques were classified as calcified, mixed, or noncalcified. Kruskal‐Wallis test, rank correlations, and linear regression analyses were used to study the relationship between PsA, metabolic syndrome, and plaque burden. Results Plaques were found in 76% of PsA patients versus 44% of controls ( P = 0.001), and a higher proportion of patients with PsA had affected coronary vessels ( P = 0.007). SIS , SSS , and TPV were greater in PsA patients than controls ( P = 0.003, P = 0.001, and P ≤ 0.001, respectively). More PsA patients had mixed plaques, and mixed plaque volume was higher than in controls ( P &lt; 0.001). PsA patients with metabolic syndrome and those without metabolic syndrome had similar plaque burdens and types. SIS , SSS , and TPV did not show significant relationships with features of metabolic syndrome, but did significantly correlate with disease activity measures. TPV was associated with a diagnosis of PsA (B = 0.865, P = 0.008), but not with metabolic syndrome. Age, highest C‐reactive protein level, highest swollen joint count, disease duration, and plasma glucose level were independent predictors of higher plaque burden in PsA. Conclusion PsA is associated with accelerated coronary plaque formation, particularly mixed plaques, independent of metabolic disease. Psoriatic disease activity and severity may predict coronary plaque burden better than traditional risk factors.
Abstract 15979: Endothelial Cell Metabolism is Controlled by the Flow-induced Long Non-coding Rna Lncflow2
Authors: Larissa Pfisterer, Anja Derlet, Nicolas Jae, Teresa Hartung, Katharina Michalik, Jermaine Goveia, Federico Taverna, Wei Chen, Peter Carmeliet, Andreas M Zeiher, Reinier A Boon, Stefanie Dimmeler
Journal: Circulation (2017)

Introduction:  The majority of the human transcriptome consists of non-coding transcripts which may exert regulatory effects on epigenetic and transcriptional processes. Since laminar flow is an important atheroprotective regulator, we analysed its impact on the expression of long non-coding RNAs (lncRNA) in human endothelial cells (EC) by RNA deep sequencing. Among the significantly up-regulated lncRNAs, we confirmed a 3-fold up-regulation of lncflow2 by laminar flow (p   Results:  Silencing of lncflow2 by GapmeRs reduced sprout formation of ECs (34.7 % reduction, p
Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies
Authors: Gianna Triller, Stephen W. Scally, Giulia Costa, Maria Pissarev, Cornelia Kreschel, Alexandre Bosch, Eric Marois, Brandon K. Sack, Rajagopal Murugan, Ahmed M. Salman, Chris J. Janse, Shahid M. Khan, Stefan H.I. Kappe, Ayola A. Adegnika, Benjamin Mordmüller, Elena A. Levashina, Jean-Philippe Julien, Hedda Wardemann
Journal: Immunity (2017)
Abstract 14156: Utility of Pre-Induction Ventriculoatrial Response to Adenosine in the Diagnosis of Orthodromic Reciprocating Tachycardia
Authors: Christopher Liu, James Ip, Jim Cheung, George Thomas, Steven Markowitz, Bruce Lerman
Journal: Circulation (2016)

Introduction:  Adenosine is known to consistently block AV nodal conduction in anterograde and retrograde directions.   Hypothesis:  We hypothesized that persistent ventriculoatrial (VA) despite administration of adenosine would have a high predictive value for identifying the presence of a retrograde accessory pathway (AP) and associated orthodromic reciprocating tachycardia (ORT).   Methods:  One hundred and sixty-eight patients undergoing electrophysiology study for supraventricular tachycardia (SVT) had assessment of VA conduction during ventricular pacing with adenosine administration. Standard pacing maneuvers were then used for induction and diagnosis of SVT mechanism.   Results:  Absence of VA block to adenosine (doses up to 24 mg) had an 88% sensitivity and 91% specificity for identifying ORT (positive predictive value 76%, negative predictive value 96%). Four patients with adenosine-induced VA block and inducible ORT had decremental APs. Adenosine caused VA block in all 6 patients with eccentric VA activation due to atypical AV nodal conduction, and concentric VA conduction persisted in all 12 patients with a septal AP. Adenosine unmasked free-wall APs in 10 patients by blocking AV nodal conduction and shifting baseline concentric VA activation to eccentric.   Conclusions:  The response of VA conduction to adenosine is a highly sensitive and specific method for detecting retrograde AP conduction and inducible ORT. VA block with adenosine nearly rules out inducible ORT. The effect is particularly helpful in cases of VA fusion, where adenosine block of AV nodal conduction can delineate the location of the AP atrial insertion site.
Treatment of Secondary Mitral Regurgitation in Chronic Heart Failure
Authors: Andrejs Erglis, Inga Narbute, Mathieu Poupineau, Thomas Hovasse, Ginta Kamzola, Ligita Zvaigzne, Martins Erglis, Kristaps Erglis, Samantha Greene, Jason H. Rogers
Journal: Journal of the American College of Cardiology (2017)
Abstract 15245: Comparison of Zotarolimus-Eluting Stents versus Sirolimus-Eluting Stents and Paclitaxel-Eluting Stents for Diffuse Very Long Lesions; A Subgroup Analysis of the Zest 2-Year Follow-up
Authors: Won-Jang Kim, Duk-Woo Park, Byung Joo Sun, Sung Won Cho, Yoo Ri Kim, Jong-Young Lee, Soo-Jin Kang Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Circulation (2010)

Background:  Although drug-eluting stents (DES) has shown to be effective in angiographic restenosis, percutaneous coronary intervention (PCI) of long coronary lesions are still challenging and limited for the long-term experience in the current era.   Methods:  We performed subgroup analysis of patients with very long coronary lesions (lesion length ≥ 28 mm) in the ZEST trial comparing second-generation zotarolimus-eluting stents with first-generation sirolimus- and paclitaxel-eluting stents. The primary end point was composite major adverse cardiac events (MACE) of death, myocardial infarction (MI), or ischemic-driven target vessel revascularization (TVR).   Results:  A total of 960 patients with very long coronary lesions were treated with zotarolimus- (ZES, 322 patients), sirolimus- (SES, 317 patients), or paclitaxel-eluting stents (PES, 321 patients). All patients with very long lesions were available for 2-year clinical follow-up. At 24 months, the ZES group showed similar rates of MACE compared with the PES group (16.1% vs. 17.4, P=0.58), but trend toward higher rates of events compared with the SES group (16.0% vs. 11.0%, p=0.059). Theses difference were mainly driven by TVR (SES vs. ZES, p=0.059; ZES vs. PES, p=0.37; SES vs. PES, p=0.006). There was no significant difference of death or MI among the groups.   Conclusion:  For patients with very long coronary artery disease, PCI with ZES results in similar rates of MACE compared with PES, but in trend toward higher rates of MACE compared with SES at 2-year.
Forebrain-specific, conditional silencing of Staufen2 alters synaptic plasticity, learning, and memory in rats
Authors: Stefan M. Berger, Iván Fernández-Lamo, Kai Schönig, Sandra M. Fernández Moya, Janina Ehses, Rico Schieweck, Stefano Clementi, Thomas Enkel, Sascha Grothe, Oliver von Bohlen und Halbach, Inmaculada Segura, José María Delgado-García, Agnès Gruart, Michael A. Kiebler, Dusan Bartsch
Journal: Genome biology (2017)

Dendritic messenger RNA (mRNA) localization and subsequent local translation in dendrites critically contributes to synaptic plasticity and learning and memory. Little is known, however, about the contribution of RNA-binding proteins (RBPs) to these processes in vivo. To delineate the role of the double-stranded RBP Staufen2 (Stau2), we generate a transgenic rat model, in which Stau2 expression is conditionally silenced by Cre-inducible expression of a microRNA (miRNA) targeting Stau2 mRNA in adult forebrain neurons. Known physiological mRNA targets for Stau2, such as RhoA, Complexin 1, and Rgs4 mRNAs, are found to be dysregulated in brains of Stau2-deficient rats. In vivo electrophysiological recordings reveal synaptic strengthening upon stimulation, showing a shift in the frequency-response function of hippocampal synaptic plasticity to favor long-term potentiation and impair long-term depression in Stau2-deficient rats. These observations are accompanied by deficits in hippocampal spatial working memory, spatial novelty detection, and in tasks investigating associative learning and memory. Together, these experiments reveal a critical contribution of Stau2 to various forms of synaptic plasticity including spatial working memory and cognitive management of new environmental information. These findings might contribute to the development of treatments for conditions associated with learning and memory deficits.
A systematic review and meta-analysis of randomized controlled trials to evaluate the risk of fatigue and pain among patients treated with ibrutinib.
Authors: Myo Zaw, Kyaw Zin Thein, Myat M. Han, Ruth D’Cunha, Hassan Kaleem, Fred L. Hardwicke, Lukman Tijani
Journal: Journal of Clinical Oncology (2017)

213 Background: Bruton’s tyrosine kinase (BTK), a kinase downstream of the B-cell receptor, involves in the B cell survival and proliferation and has become an attractive therapeutic target. Ibrutinib is an oral potent, covalent inhibitor of BTK and hence employed in many hematologic malignancies. We performed a systematic review and pooled analysis of randomized controlled trials (RCTs) to determine the risk of fatigue and pain among patients treated with ibrutinib. Methods: We performed a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts through December 31, 2016. RCTs that mention fatigue, arthralgia, muscle spasm, back pain, pain in extremity and myalgia as adverse effects were incorporated in the analysis. Mantel-Haenszel method was used to calculate the estimated pooled risk ratio with 95% confidence interval (CI). Results: Four phase 3 RCTs with a total of 1505 patients were eligible for the analysis. Studies compared Ibrutinib (I) vs ofatumumab, I vs chlorambucil, I+ bendamustine (B)+ rituximab (R) vs placebo + B+ R and I vs temsirolimus were included in the analysis. The relative risks (RR) of all-grade side effects were as follows: fatigue, 0.87 (95% CI: 0.74- 1.03, p = 0.11); arthralgia, 1.97 (95% CI: 1.11- 3.50, p = 0.02); muscle spasm, 1.92 (95% CI: 1.22- 3.02, p = 0.005); back pain, 1.56 (95% CI: 1.02- 2.37, p = 0.03); pain in extremity, 2.47 (95% CI: 1.14- 5.36, p = 0.02); and myalgia, 2.68 (95% CI: 1.18- 6.05, p = 0.01). The RR of high-grade side effects were as follows: fatigue, 0.70 (95% CI: 0.37- 1.33, p = 0.28); arthralgia, 3.62 (95% CI: 0.74- 17.66, p = 0.11); back pain, 2.80 (95% CI: 0.42- 18.35, p = 0.28); pain in extremity, 2.96 (95% CI: 0.31- 28.4, p = 0.34); and myalgia, 2.96 (95% CI: 0.31- 28.44, p = 0.34). Conclusions: Our meta-analysis demonstrated that the risk of all-grade arthralgia, muscle spasm, back pain, pain in extremity and myalgia with ibrutinib was high. Pain is a major determinant of quality of life in cancer patients undergoing chemotherapy and recognizing these may help clinicians in delivering proper supportive care.
Le défi de la surveillance de l’hépatite C en Europe
Authors: J C Desenclos
Journal: Eurosurveillance (2003)

L’ hepatite C est devenue un probleme important de sante publique, en raison de sa prevalence elevee, des complications hepatiques severes, de la transmission persistante chez les utilisateurs de drogues injectables (UDI), du risque de transmission iatrogenique et de la disponibilite des mesures preventives et de traitements efficaces.
P3.02b-126 Clinical Activity of Olmutinib (HM61713) Used on a Compassionate IND Basis for Patients with Lung Adenocarcinoma (LADC) in Korea
Authors: Jin Soo Lee, Ji-Youn Han, Youngjoo Lee, Geon Kook Lee, Hye Jin An, Hyae Young Kim
Journal: Journal of Thoracic Oncology (2017)
Mobilising experience from Ebola to address plague in Madagascar and future epidemics
Authors: Kelley Sams, Alice Desclaux, Julienne Anoko, Francis Akindès, Marc Egrot, Khoudia Sow, Bernard Taverne, Blandine Bila, Michèle Cros, Moustapha Keïta-Diop, Mathieu Fribault, Annie Wilkinson
Journal: The Lancet (2017)
Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis
Authors: Chunqing Lin, Silvia Franceschi, Gary M Clifford
Journal: The Lancet Infectious Diseases (2017)

Data on carcinogenicity of human papillomavirus (HPV) types in the anus are needed to inform anal cancer prevention through vaccination and screening. This is particularly the case for people infected with HIV, who are at an increased risk of anal cancer.
Dati di sorveglianza relativi all'infezione da HIV e AIDS in età pediatrica in Grecia
Authors: G Nikolopoulos, V Konte, A Masgala, E Eleni, A Tsantes, D Paraskeva
Journal: Eurosurveillance (2004)

In Grecia la sorveglianza dell'HIV/AIDS viene condotta dall'Hellenic Centre for Infectious Diseases Control. Il sistema di registrazione dei casi di AIDS e stato messo a punto nel 1984 ed e stato seguito dalla notifica delle infezioni da HIV del 1998. Questo articolo riporta l'analisi della sorveglianza e dell'andamento delle infezioni da HIV e dell'AIDS in eta pediatrica e comprende i casi identificati precedenti al 1998. 
In Grecia il numero di bambini infetti da HIV e relativamente basso: sono stati segnalati 69 casi da giugno 2003; si ritiene che 44 (pari al 64%) di questi bambini abbiano contratto il virus dell'immunodeficienza umana mediante trasmissione dalla madre. Sono stati riportati trentatre casi pediatrici di AIDS dall'insorgenza dell'epidemia in cui la piu frequente infezione opportunistica era la polmonite da Pneumonocystis carinii. 
A un numero significativo di bambini l'AIDS e stata diagnosticata dopo il primo anno di eta. Questo fenomeno puo essere imputato al fatto che in molte donne infette non viene identificato l'HIV durante la gravidanza, anche se sono disponibili test volontari, o puo essere attribuito al fatto che questi dati comprendono le infezioni da HIV raccolte retrospettivamente dopo il 1998 e che e possibile che bambini stranieri infetti da HIV siano giunti in Grecia a quell'eta. Inoltre, nuovi casi pediatrici positivi all'HIV, riportati durante la prima meta del 2003, erano di bambini stranieri nati nell'Europa dell'Est e nell'Africa Sub Sahariana. Per poter attuare un intervento adeguato, e necessario compiere ogni sforzo per l'identificazione precoce di casi di infezione in donne all'interno di queste popolazioni. L'infezione da HIV nei bambini rimane un problema mondiale di notevole entita ed e molto importante riuscire a ridurre il rischio di trasmissione del virus dalla madre al figlio.
Retroviral Gene Therapy for X-Linked Chronic Granulomatous Disease: Results from Phase I/II Trial.
Authors: Joong Gon Kim, Hyo Seop Ahn, Hyoung Jin Kang, Sujeong Kim, Youngtae Hong, Chang-Wan Joo, Nam-Kyung Yoon, Sunyoung Kim
Journal: Blood (2008)
Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms
Authors: Geoffroy Venton, Frédéric Courtier, Aude Charbonnier, Evelyne D'incan, Colombe Saillard, Bilal Mohty, Marie‐Joëlle Mozziconacci, Daniel Birnbaum, Anne Murati, Norbert Vey, Jérôme Rey
Journal: American Journal of Hematology (2017)

Abstract Acute myeloid leukemias secondary (sAML) to myeloproliferative neoplasms (MPN) have variable clinical courses and outcomes, but remain almost always fatal. Large cohorts of sAML to MPN are difficult to obtain and there is very little scientific literature or prospective trials for determining robust prognostic markers and efficient treatments. We analyzed event‐free survival (EFS) and overall survival (OS) of 73 patients with MPN who progressed to sAML, based on their epidemiological characteristics, the preexisting MPN, the different treatments received, the different prognostic groups and the responses achieved according to the ELN, and their mutational status determined by next‐generation DNA sequencing (NGS). For 24 patients, we were able to do a comparative NGS analysis at both MPN and sAML phase. After acute transformation EFS and OS were respectively of 2.9 months (range: 0‐48.1) and 4.7 months (range: 0.1‐58.8). No difference in EFS or OS regarding the previous MPN, the ELN2017 prognostic classification, the first‐line therapy or the response was found. After univariate analysis, three genes, TP53 , SRSF2 and TET2, impacted pejoratively sAML prognosis at sAML time. In multivariate analysis, TP53 ( P = .0001), TET2 ( P = .011) and SRSF2 ( P = .018) remained independent prognostic factors. Time to sAML transformation was shorter in SRSF2 ‐mutated patients (51.2 months, range: 14.7‐98) than in SRSF2‐ unmutated patients (133.8 months, range: 12.6‐411.2) ( P &lt; .001). Conventional clinical factors (age, karyotype, ELN2017 prognostic classification, treatments received, treatments response, Allo‐SCT…) failed to predict the patients' outcome. Only the mutational status appeared relevant to predict patients' prognosis at sAML phase.
Human T Cell Leukemia Virus Type 1: Persistence and Pathogenesis
Authors: Charles R.M. Bangham
Journal: Annual Review of Immunology (2017)

Human T cell leukemia virus type 1 (HTLV-1), also known as human T lymphotropic virus type 1, was the first exogenous human retrovirus discovered. Unlike the distantly related lentivirus HIV-1, HTLV-1 causes disease in only 5–10% of infected people, depending on their ethnic origin. But whereas HIV-1 infection and the consequent diseases can be efficiently contained in most cases by antiretroviral drug treatment, there is no satisfactory treatment for the malignant or inflammatory diseases caused by HTLV-1. The purpose of the present article is to review recent advances in the understanding of the mechanisms by which the virus persists in vivo and causes disabling or fatal diseases.
A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey
Authors: Xuesong Wang, Yu Yan, Tianyu Gan, Xi Yang, Dapeng Li, Dongming Zhou, Qiang Sun, Zhong Huang, Jin Zhong
Journal: Gut (2017)

Objective Despite the development of highly effective direct-acting antivirals, a prophylactic vaccine is needed for eradicating HCV. A major hurdle of HCV vaccine development is to induce immunity against HCV with high genome diversity. We previously demonstrated that a soluble E2 (sE2) expressed from insect cells induces broadly neutralising antibodies (NAbs) and prevents HCV infection. The objective of this study is to develop a multivalent HCV vaccine to increase the antigenic coverage. Design We designed a trivalent vaccine containing sE2 from genotype 1a, 1b and 3a. Mice and rhesus macaques were immunised with monovalent or trivalent sE2 vaccine, and sera or purified immunoglobulin were assessed for neutralisation against a panel of cell culture-derived virion (HCVcc) of genotype 1–7 in cell culture. Splenocytes from the vaccinated macaques were assessed for HCV-specific T cell response. Results We showed that the trivalent vaccine elicited pangenotypic NAbs in mice, which neutralised HCVcc of all the seven genotypes more potently than the monovalent vaccine. Further analyses demonstrated that each sE2 component of this trivalent vaccine elicited unique spectrum of NAbs which acted synergistically to inhibit HCV infection. Finally, the trivalent vaccine triggered stronger and more uniform multigenotypic neutralising antibody response than the monovalent vaccine in rhesus macaques. Conclusions In summary, we developed a trivalent HCV vaccine that induces broad and synergistic-acting neutralising antibodies in mice and non-human primates.
P2.03b-023 Circulating Tumor DNA (ctDNA)-Based Genomic Profiling of Known Cancer Genes in Lung Squamous Cell Carcinoma (LUSC)
Authors: Vincent Lam, Hai Tran, Kimberly Banks, Waree Rinsurongkawong, Vassiliki Papadimitrakopoulou, Ignacio Wistuba, Andrew Futreal, Richard Lanman, Stephen Swisher, Amirali Talasaz, John Heymach, Jianjun Zhang
Journal: Journal of Thoracic Oncology (2017)
Integrated genomic and interfacility patient-transfer data reveal the transmission pathways of multidrug-resistant <i>Klebsiella pneumoniae</i> in a regional outbreak
Authors: Evan S. Snitkin, Sarah Won, Ali Pirani, Zena Lapp, Robert A. Weinstein, Karen Lolans, Mary K. Hayden
Journal: Science Translational Medicine (2017)

Integrating whole-genome sequencing and interfacility patient-transfer data reveals transmission pathways of a multidrug-resistant organism.